SCHEMBL635407

SCHEMBL635407

O=S(=O)(Oc1ccc2ccccc2c1-c1c(OS(=O)(=O)C(F)(F)F)ccc2ccccc12)C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
WDR5 P61964 1/20 0.40
DNMT1 P26358 1/20 0.39
CES1 P23141 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
SLC2A1 P11166 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2A6 P11509 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29560409 1.00 MAPT (0.49) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL12111893 0.93 MAPT (0.46) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL7518681 0.93 MAPT (0.42) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL27796343 0.93 MAPT (0.63) MAPTRAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL23581680 0.92 MAPT (0.41) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL9405037 0.91 HSP90AA1 (0.41) MAPTWDR5ALDH1A1MEN1KMT2A
SCHEMBL31498197 0.91 MAPT (0.41) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL3811084 0.90 MAPT (0.43) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL25024158 0.90 MAPT (0.39) MAPTWDR5DNMT1CES1RAB9A
SCHEMBL7799372 0.89 MAPT (0.38) MAPTWDR5DNMT1CES1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0771812-B1 Method for producing an optically active diphosphine TAKASAGO PERFUMERY CO LTD (JP) 2003-12-10 EP claimed
EP-0839819-A1 Method of preparing optically active diphosphine ligands Takasago International Corporation (JP) 1998-05-06 EP claimed
US-5693868-A REACTING 2,2'-BIS(TRIFLUOROMETHANESULFONYLOXY)-1,1-BINAPHTHYL WITH A PHOSPHINE OXIDE IN THE PRESENCE OF A TRANSITION METAL-PHOSPHINE COMPLEX TAKASAGO INTERNATIONAL CORPORATION (JP) 1997-12-02 US claimed
EP-0771812-A1 Method for producing an optically active diphosphine Takasago International Corporation (JP) 1997-05-07 EP claimed
JP-9124669-A None JP disclosed
US-11500247-B2 Liquid crystal sensor PLATYPUS TECHNOLOGIES, LLC (US) 2022-11-15 US disclosed
EP-3421449-B1 PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVES UNIV KYOTO (JP) 2021-03-31 EP disclosed
EP-3037398-B1 METHOD FOR MANUFACTURING CHEMICAL COMPOUND SUMITOMO CHEMICAL CO (JP) 2021-03-10 EP disclosed
US-20200409221-A1 LIQUID CRYSTAL SENSOR PLATYPUS TECHNOLOGIES, LLC 2020-12-31 US disclosed
US-10717809-B2 Production method of polymer compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-07-21 US disclosed
US-10611714-B2 Method for producing 1,1′-binaphthyl derivatives and 1,1′-binaphthyl derivatives KYOTO UNIVERSITY (JP) 2020-04-07 US disclosed
US-20190185613-A1 PRODUCTION METHOD OF POLYMER COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-06-20 US disclosed
EP-0754696-A1 Chiral unsymmetric diphosphine compounds and transition metal complexes containing them as ligands Takasago International Corporation (JP) 1997-01-22 EP disclosed
EP-0732337-A1 Optically active asymmetric diphosphine and process for producing optically active substance in its presence Takasago International Corporation (JP) 1996-09-18 EP disclosed
US-5530150-A HAVING PHOSPHINE AND PHOSPHITE GROUPS IN SAME MOLECULE; CATALYST SELECTIVITY TAKASAGO INTERNATIONAL CORPORATION (JP) 1996-06-25 US disclosed
EP-0684249-A1 Phosphine compounds, complexes containing the phosphine compounds as ligands, and process for producing optically active aldehydes using the phosphine compounds or complexes Takasago International Corporation (JP) 1995-11-29 EP disclosed
EP-0684230-A1 4- (R)-1'-formylethyl azetidin-2-one derivatives Takasago International Corporation (JP) 1995-11-29 EP disclosed
EP-0614870-A2 Process for producing optically active aldehydes MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1994-09-14 EP disclosed
EP-0614901-A1 Phosphine compound and transition metal-phosphine complex containing the same as ligand MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1994-09-14 EP disclosed
EP-0614903-A2 Phosphine compounds, complexes containing the phosphine compounds as ligands, process for producing optically active aldehydes using the phosphine compounds, or complexes, and 4-[(R)-1' formylethyl]azetidin-2-one derivatives Takasago International Corporation (JP) 1994-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10611714-B2 Method for producing 1,1′-binaphthyl derivatives and 1,1′-binaphthyl derivatives KYAT1, HAO2, MBOAT1 MAPT 3357/4885WDR5 4474/4885DNMT1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.